BI 771716

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Geographic AtrophyMacular Degeneration, Age-related

Phase 1

A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

CompletedNCT06006585

Boehringer IngelheimGeographic Atrophy

Start: 2023-10-06End: 2024-05-24Updated: 2025-02-18

Phase 2

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Active, not recruitingNCT06722157

Boehringer IngelheimGeographic Atrophy, Macular Degeneration, Age-related

Start: 2025-01-06End: 2026-10-28Updated: 2026-05-14